Cidara Therapeutics to Present Ongoing Development of
SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics...
Source: globenewswire.com
📰 Cidara Cloudbreak News
Cidara Cloudbreak News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cidara Cloudbreak. Real-time updates on events, politics, business and more.
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit
SAN DIEGO, June 20, 2023 -- Cidara Therapeutics, Inc. , a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious... | June 20, 2023
Source: marketscreener.com
HVIVO touts positive test results from seasonal flu drug, CD388
HVIVO PLC on Monday said that Cidara Therapeutics Inc has seen positive results from an ongoing study testing CD388, a drug designed to treat seasonal flu. hVIVO is a London-based specialist... | April 3, 2023
Source: marketscreener.com
Positive results from hVIVO study of Cidara flu candidate
Study demonstrated a reduction in viral replication in the upper respiratory tract as well as influenza infection - News - PharmaTimes
Source: pharmatimes.com
Influenza A Market to Witness Robust Expansion at a CAGR of 8.5% in the United States During the Study Period (2019-2032), Assesses DelveInsight
/PRNewswire/ -- DelveInsights Influenza A Market Insights report includes a comprehensive understanding of current treatment practices, influenza A emerging...
United States United Kingdom Shruti Thakur Sab Biotherapeutics Ridgeback Biotherapeutics Cocrystal Pharma
Source: prnewswire.com
DelveInsight Business Research, LLP: Influenza A Market to Witness Robust Expansion at a CAGR of 8.5% in the United States During the Study Period (2019-2032), Assesses DelveInsight
The influenza A market is expected to surge in the coming years as the emerging therapies which are under development will provide efficient therapeutic approaches with novel mechanisms of action
United States United Kingdom Shruti Thakur Prnewswire Delveinsight Sab Biotherapeutics Kostenloser Wertpapierhandel
Source: finanznachrichten.de
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
13.09.2022 - CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak platform designed to help transform the standard of care for seasonal and pandemic influenza prevention Study is being conducted in collaboration with Janssen SAN DIEGO, Sept. 13, 2022 ... Seite 1
Cidara Cloudbreak Jeffrey Stein Cidara Therapeutics Inc Janssen Pharmaceuticals Inc Janssen Pharmaceutical Companies Of Johnson Janssen Pharmaceuticals
Source: wallstreet-online.de
Cidara Therapeutics to Host Research and Development Day
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Cidara Therapeutics Provides Corporate Update and Reports
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics...
Source: globenewswire.com